A study to evaluate neutralizing response against SARS-CoV-2 variants at 8 months after Pfizer-BNT162b2 vaccination in COVID-19 naive and COVID-19 convalescent individuals
Latest Information Update: 05 Jan 2022
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 05 Jan 2022 New trial record
- 28 Dec 2021 Results published in the Journal of Infectious Diseases